Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 9/20 | 0.47 |
| ▸ | ATRIP | Q8WXE1 | 8/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.43 |
| ▸ | MTOR | P42345 | 9/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.41 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.41 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.41 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556125 | 1.00 | ATR (0.47) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21262100 | 1.00 | ATR (0.47) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL24196284 | 0.84 | ATR (0.47) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21262287 | 0.84 | ATR (0.47) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL30137161 | 0.84 | ATR (0.47) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21262286 | 0.84 | ATR (0.47) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL22556145 | 0.83 | MTOR (0.45) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL22556144 | 0.83 | MTOR (0.45) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21262225 | 0.81 | FPR2 (0.44) | ATRATRIPPIK3CAMTORPIK3R1 | |
| SCHEMBL21262644 | 0.80 | MTOR (0.45) | ATRPIK3CAMTORPIK3R1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| EP-3749672-B1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2022-07-27 | — | — | EP | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| EP-3728267-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| WO-2019153080-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | ATR 3964/4885ATRIP 1110/4885CHEK1 1794/4885 |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | ATR 4151/4885ATRIP 1278/4885CHEK1 1970/4885 |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | ATR 4089/4885ATRIP 1098/4885CHEK1 1691/4885 |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | BCL6, BCL6B, BCL3 | ATR 4089/4885ATRIP 1098/4885CHEK1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.